Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Published June 2026 | Last reviewed June 2026
Key takeaways
- Troponin and NT-proBNP help frame disease burden in ATTR-CM but don’t establish the diagnosis on their own.
- Serum free light chain testing with serum and urine immunofixation electrophoresis is exclusionary for AL amyloidosis rather than confirmatory for ATTR-CM.
- Serial trends are often more useful than isolated values.
- Biomarker interpretation becomes meaningful only when anchored to imaging and phenotype.
What Troponin and NT-proBNP Contribute
Troponin and NT-proBNP are most useful as supportive signals within a structured diagnostic pathway rather than as self-sufficient answers. They can help frame baseline myocardial stress and disease burden, and they contribute to staging and prognosis, but they don’t determine whether the underlying cardiomyopathy is transthyretin-mediated. Instead, they complement the phenotype recognition and imaging steps that guide screening and early detection.
Exclusionary vs. Confirmatory Biomarker Logic
The key distinction is that the most decisive biomarker step in ATTR-CM is exclusionary, not confirmatory. Serum free light chain testing together with serum and urine immunofixation electrophoresis is used to help rule out AL amyloidosis rather than to confirm ATTR-CM. That matters because low-level abnormalities can be hard to interpret in older patients or with renal dysfunction. Discordant results still require clinical correlation and sometimes hematologic or tissue confirmation. A clean monoclonal screen strengthens an ATTR pathway; an abnormal one redirects it, which is the heart of excluding AL and reading the phenotype.
Why Serial Trends Beat Isolated Values
For longitudinal care, trends are usually more informative than isolated values. Troponin and NT-proBNP reflect overlapping but distinct dimensions of myocardial injury and hemodynamic stress, so their significance is best interpreted alongside symptoms, imaging, congestion status, renal function, and the broader disease trajectory.. In that sense, biomarkers therefore support clinical interpretation across the disease course; they do not replace the broader workup.
Frequently Asked Questions
What do troponin and NT-proBNP contribute in ATTR-CM?
They help frame myocardial stress and disease burden and contribute to staging, but they don’t establish ATTR-CM or distinguish it cleanly from competing causes on their own.
Why is serum free light chain testing important if it doesn’t confirm ATTR-CM?
It helps exclude AL amyloidosis, which changes how the entire workup and imaging interpretation should be understood. Its role is exclusionary rather than confirmatory.
Why are serial trends more useful than one-time values?
Biomarker values become clearer when interpreted alongside symptoms, imaging, congestion status, renal function, and disease trajectory over time, rather than as a single snapshot.
Part of the Spotlight On ATTR-CM resource center.
References:
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). PubMed
- Best Practices in Specialized Amyloidosis Centers in the United States. PubMed
- 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee. PubMed
This content is intended for healthcare professionals for educational purposes and is not a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.